Monday 19 October 2026 Export MOTS’s income statement to Excel — free account

Motus GI Holdings, Inc.

Motus GI Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $319,000.00, down 46.1% from fiscal 2022. Operating cash flow growth for three consecutive years.

0.00 0.00 NaN

Follow MOTS

Alert me

Market cap: $420.0K
P/E: 0.0×
Fwd P/E: 0.0×
Dividend yield: —
F-score: 2/9
Altman Z: −34.74
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 42.30%

Capital & Financial Ratios $m

Market Cap 0.42

Revenue 0.33

Net Income (10.59)

Free Cash Flow (8.41)

Net Debt (2.64)

Current Ratio 1.74

Debt/Equity 0.75

P/E ratio 0.00

Fwd P/E (0.03)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (10.50%)

Next Y EPS Growth 27.74%

Next Y revenue growth 715.05%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2021	2022	2023	Q'24
Cash	23	14	5	5
Receivables	0	0	0	0
Inventory	0	0	0	0
Other	—	—	—	—
	24	15	6	6

	2021	2022	2023	Q'24
Payables	3	2	2	1
ST’ Debt	0	3	1	2
Other	0	0	0	0
	3	5	3	3

Compound Annual Growth %

	10y	5y	3y
Sales	—	54.70%	48.20%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(32.03%)	(38.03%)

Revenue $m

	Jun	Sep	Dec	Year
’26	—	—	—	—
’23	0	0	0	0
’22	0	0	0	1
’21	0	0	0	0
’20	0	0	0	0
’19	0	0	0	0
’18	0	—	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	—	—	—	—
’23	(5)	(3)	(2)	(2)	(11)
’22	(5)	(5)	(4)	(4)	(17)
’21	(5)	(3)	(3)	(4)	(14)
’20	(7)	(4)	(3)	(3)	(17)
’19	(6)	(4)	(5)	(6)	(20)
’18	(3)	(4)	(3)	(4)	(15)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	—	—	—	—
’23	(5)	(3)	(2)	(2)	(11)
’22	(5)	(5)	(4)	(4)	(18)
’21	(5)	(3)	(3)	(4)	(15)
’20	(7)	(4)	(3)	(3)	(17)
’19	(6)	(4)	(5)	(6)	(20)
’18	(4)	(4)	(3)	(5)	(15)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.88)	—	—	—	—
’23	(13.79)	(6.00)	(4.28)	(4.48)	(15.89)
’22	(26.99)	(27.89)	(25.34)	(11.84)	(86.06)
’21	(74.96)	(29.98)	(29.98)	(29.98)	(161.92)
’20	(68.97)	(44.98)	(38.98)	(35.98)	(179.91)
’19	(86.96)	(77.96)	(53.97)	(59.97)	(275.86)
’18	(170.91)	(80.96)	(98.95)	(101.95)	(440.78)

Fiscal quarters ending in the months shown.

Group	Line	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e
Price, $
Price, $	Low	—	—	—	—	702.03	428.55	138.00	119.97	10.20	1.14	Analyst estimates 2024–2026 Powerpack
	High	—	—	—	—	3,198.00	1,497.00	855.00	822.00	195.00	23.40
People
People	Employees	—	—	36	39	44	49	24	30	49	15
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.02
Income, $m
Income, $m	Revenue	—	—	—	0	0	0	0	0	1	0
	Gross margin, %	—	—	0.00	(871.43)	(50.00)	(27.10)	(406.12)	(59.59)	(34.46)	(78.37)
	EBT	—	—	(8)	(13)	(22)	(23)	(19)	(19)	(19)	(13)
	EBT margin, %	—	—	0.00	(188,571.43)	(61,825.00)	(21,575.70)	(19,650.00)	(4,867.77)	(3,141.39)	(4,033.54)
	Net income	—	—	(8)	(13)	(22)	(23)	(19)	(19)	(19)	(13)
	Depreciation	—	—	0	0	0	0	0	1	1	1
Per share, $
Per share, $	Revenue	—	—	0.00	0.20	0.71	1.28	0.92	2.50	2.74	0.39
	Earnings	—	—	(2,099.21)	(383.81)	(440.78)	(275.86)	(179.91)	(161.92)	(86.06)	(15.89)
	Cash flow	—	—	(1,612.11)	(301.39)	(295.70)	(237.65)	(158.66)	(92.21)	(80.87)	(13.82)
	Capex	—	—	(7.89)	(20.49)	(10.83)	(5.58)	(0.82)	(3.01)	(1.04)	(0.13)
	Free cash flow	—	—	(1,620.00)	(321.88)	(306.53)	(243.23)	(159.49)	(95.22)	(81.90)	(13.95)
	Book value	—	—	2,639.21	160.09	366.67	218.71	105.42	61.75	13.78	3.32
	Shares, m	—	—	0	0	0	0	0	0	0	1
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	0.00	0.00	538.04	310.81	56.04	4.87	3.30
	P/B	—	—	—	8.21	2.54	3.14	2.70	2.27	0.97	0.39
	EV/Sales	—	—	—	0.00	0.00	348.66	185.37	27.45	(0.25)	(5.12)
	EV/FCF	—	—	—	(3.88)	(1.99)	(1.83)	(1.06)	(0.72)	0.01	0.14
Cash, $m
Cash, $m	Operating cash flow	—	—	(6)	(10)	(15)	(20)	(17)	(14)	(17)	(11)
	Capex	—	—	0	(1)	(1)	0	0	0	0	0
	Free cash flow	—	—	(6)	(11)	(15)	(20)	(17)	(15)	(18)	(11)
Balance, $m
Balance, $m	Working capital	—	—	11	6	20	19	11	21	11	2
	Total debt	—	—	—	—	—	8	9	11	11	2
	Net debt	—	—	(12)	(7)	(21)	(20)	(12)	(11)	(3)	(3)
	Shareholders’ equity	—	—	10	6	19	18	11	10	3	3
Returns, %
Returns, %	ROA	—	—	(115.39)	(123.60)	(138.58)	(83.63)	(68.38)	(100.40)	(85.04)	(103.47)
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(744,187.50)
	ROE	—	—	(254.46)	(169.75)	(185.17)	(125.31)	(130.04)	(240.40)	(294.40)	(454.34)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2023 · latest quarter Mar 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NUWE Nuwellis, Inc.	$2.0M	— (loss-making)	— (loss-making)	+14.14% (above 0%: growing)	n/m	−51.55% (below 0%: shrinking)	76.08%	(160.94%)	Compare
AFIB Acutus Medical, Inc.	$1.7M	— (loss-making)	— (loss-making)	+204.18% (above 0%: growing)	n/m	+76.40% (above 0%: growing)	14.20%	(3.81%)	Compare
DHAI DIH Holding US, Inc.	$1.6M	— (loss-making)	—	−30.67% (below 0%: shrinking)	n/m	−167.90% (below 0%: shrinking)	50.33%	(33.62%)	Compare
DYNTQ Dynatronics Corporation	$1.2M	— (loss-making)	— (loss-making)	−7.61% (below 0%: shrinking)	n/m	−193.04% (below 0%: shrinking)	24.65%	(1.26%)	Compare
THMO ThermoGenesis Holdings, Inc.	$1.1M	— (loss-making)	5.5×	+6.42% (above 0%: growing)	n/m	+62.12% (above 0%: growing)	43.92%	(20.35%)	Compare
SSKN Strata Skin Sciences, Inc.	$1.0M	— (loss-making)	— (loss-making)	−2.97% (below 0%: shrinking)	n/m	−376.88% (below 0%: shrinking)	61.82%	7.66%	Compare
FEED ENvue Medical, Inc.	$950.0K	— (loss-making)	— (loss-making)	−51.62% (below 0%: shrinking)	n/m	+19.75% (above 0%: growing)	(111.30%)	(2,290.38%)	Compare
PFSA PROFUSA, Inc.	$650.0K	0.0×	—	—	n/m	−359.25% (below 0%: shrinking)	100.00%	0.00%	Compare
MOTS Motus GI Holdings, Inc.	$420.0K	— (loss-making)	— (loss-making)	+14.29% (above 0%: growing)	n/m	+58.21% (above 0%: growing)	81.25%	(3,165.63%)
Median of peers	$1.1M	—	—	−2.97%	—	−109.72%	47.12%	(12.08%)

All 149 Medical Devices stocks →